Candel Therapeutics, Inc. (f/k/a Advantagene, Inc.)
Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. CAN-2409 is the lead product candidate from the adenovirus platform, and CAN-3110 is the lead product candidate from the HSV platform.
Candel's lead clinical trial for localized prostate cancer, the ProstAtak study (PrTK03), is a Phase 3 registration study under a FDA approved Special Protocol Assessment (SPA) for the treatment of localized prostate cancer patients with intermediate to high risk disease choosing radiation therapy as their first-line treatment.
Using our virus-based platforms, we calibrate our treatments to each cancer that we target. These viruses have been genetically engineered to minimize impact on healthy tissue, while maximizing the patient’s immune response to fight the tumor.
Candel also has active clinical cancer studies in brain, lung and pancreas. For more information please visit www.candeltx.com.
Brands: ProstAtak® being developed using GMCI™